Outbreak of Extensively Drug-resistant Pseudomonas aeruginosa Associated with Artificial Tears

Outbreak is associate the Food and Drug Administration on FDA including eye infections.

Three products have been voluntarily recalled by their manufacturer, Global Pharma (Chennai, India), in association with this outbreak.

EzriCare Artificial Tears was the only common art Verona l tears product identified across four heal Guiana facility clusters.

The infect VIM-GES-CRPA sed by a strain of carbapenem- the United States ginosa that produces the Verona integron-encoded metallo--lactamase (VIM) A subset of 5 isolates that underwent antimicrobial susceptibility testi EzriCare efiderocol were susceptible to this agent.

Bacteriophage CDC hage) FDA th activity clinicians he outbreak strain have been identifi EzriCare Artificial Tears 3 wit two laVIM-80 and blaGES-9 is resistant to imipenem or me Delsam Pharma’s Artificial Tears that Delsam Pharma’s e Artificial Ointment S) and identify CDC Aerug FDA s ST1201 wi clinicians osa are encouraged to rep EzriCare s to Delsam Pharma’s Artificial Tears are-associated infections program contact. CDC an cl FDA =" Clinicians d_highLightText__NxlGi">Delsam Pharma’s A Pseudomonas aeruginosa ts CRPA an> VIM-CRPA htText__NxlGi">FDA Alert January 1, 2022 xt__NxlGi">2023 February 3, 2023 February May 15, 2023 sp CDC class="summaryFeed_highLightText__NxlGi">2023 81 aryFeed_highL 18 htText__N CA Gi CO Fe CT ua DE 2 FL /s IL n> NC NJ n NM as NV "s NY ma OH Fe PA _h SD hL TX htText WA Nx WI i">2023 VIM-GES-CRPA an class="summaryFeed_highLightText__NxlGi">March 1, 13 tText__NxlGi">March 14, 2023 13 s="summaryF 6 ed 46% ghLightText__NxlGi">Updates the February 2, 2023 yFeed_highLightText__NxlGi">CDC blaGES-9 blaVIM-80 WGS 7 maryFeed_highLightText__NxlGi">the Antimicrobial Resistance Laboratory Network VIM-CRPA CRPA May 2022 to April 2023 ext__NxlGi">the Antimicrobial Resistance Laboratory Network 14 Text__NxlGi">Isolates 21 highLightT 13 t__NxlGi">meropenem < 3 pan class= 3 summaryFeed_ 1 ighLightText__NxlGi">imipe 26 m P. aeruginosa Contact Precautions14 n> an additional 4 _NxlGi">Enhanced Barrier Precautions 4 ryFeed_highLigh 30 days NxlG VIM-GES-CRPA /span> Contact Precautions 10 yFeed_highLightText__NxlGi">VIM-CRPA EzriCare Artificial Tears CRPA VIM-CRPA 2 four ="summaryFeed_highLightText__NxlGi">Organisms CDC pan class="summaryFeed_highL VIM-GES-CRPA lGi">Januar EzriCare 2 VIM-CRPA two lGi">CRPA VIM-GES-CRPA an class="summaryFeed_highLightText__NxlGi">Antimicrobial Resistance Laboratory NetworkEzriCare Artificial Tears yFee FDA ighLightText__NxlGi">VIM-CRPA P. Three an class="summaryFeed_highLightText__NxlGi">Healthcare < Global Pharma ummaryFeed_ India ightText__NxlGi">VIM-GES-CRPA EzriCare Artificial Tears hi Delsam Pharma Artificial Tears Delsam Pharma Artificial Ointment ightText__NxlGi">CDC 3 EzriCare Artificial Tears c Delsam Pharma Artificial Tears t__Nxl Delsam Pharma Artificial Ointment ry FDA d_highLightText__NxlGi">Delsam Pharma’s Artificial Ointment De FDA m Pharma’s Artificial Tears EzriCare FDA cla Consumer Complaint Coordinators NxlGi">Healthcare EzriCare ="su Delsam Pharma’s Artificial Tears Delsa Delsam Pharma Artificial Ointment pan> CDC Delsa FDA harma’s Artificial Tears < EzriCare ss=" Delsam Pharma’s Artificial Tears ">EzriCare Delsam Pharma Artificial Ointment Delsam Ph EzriCare rtif Delsam Pharma’s an> Delsam Pharma LightText__NxlGi">EzriCare the Antibiotic Resistance Laboratory Network Carbapenem the Yale Center for Phage Biology Jonathan Koff [email protected] IPA Blurry an> FDA class="summaryFeed_highLightText__NxlGi">Clinicians the Yale FDA ter for Phage Biology University of California a FDA an Consumer Complaint Coordinators hage Applications and Therapeutics clinicians maryFeed_highLightText__NxlGi">CDC Test Directory CDC Verona t__NxlGi">16 μg/mL the Guiana-Extended Spectrum-β-Lactamase n GES ss="summaryFeed_highLightText__NxlGi">5 < 1203 class="summ blaVIM-80 ighLi blaGES-9 _NxlGi">aztreonam the United States xt VIM-GES-CRPA